​

Definium Therapeutics Stock (NASDAQ:DFTX)

ForecastFinancialsChartTranscripts
Definium Therapeutics by TradingView

Previous Close

$21.27

52W Range

$12.88 - $26.15

50D Avg

$14.26

200D Avg

$14.26

Market Cap

$2.04B

Avg Vol (3M)

$2.53M

Beta

2.56

Div Yield

-

DFTX Company Profile

Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

74

IPO Date

Nov 15, 2016

Website

DFTX Performance

DFTX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-166.31M$-103.92M$-93.87M
Net Income$-183.79M$-108.68M$-95.73M
EBITDA$-166.31M$-105.87M$-92.57M
Basic EPS$-2.06$-1.54$-2.44
Diluted EPS$-2.06$-0.15$-2.44

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Feb 26, 26 | 4:30 PM
Q3 25Nov 06, 25 | 4:30 PM
Q2 25Jul 31, 25 | 4:30 PM

Peer Comparison

TickerCompany
BBOTBridgeBio Oncology Therapeutics Inc.
TNGXTango Therapeutics, Inc.
URGNUroGen Pharma Ltd.
ANABAnaptysBio, Inc.
NRIXNurix Therapeutics, Inc.
RZLTRezolute, Inc.
KODKodiak Sciences Inc.
XNCRXencor, Inc.
FTREFortrea Holdings Inc.
SVRASavara Inc.